Tag Archives: AcelRx Pharmaceuticals
La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War
It’s common for antibiotics developers to run into financial trouble these days but what’s unusual is seeing a bidding war erupt for one of them. The competition for Tetraphase Pharmaceuticals now has a new winner: La Jolla Pharmaceutical. San Diego-based La Jolla (NASDAQ: LJPC) has pledged to pay Tetraphase shareholders $43 million in cash now […]
Posted in Boston blog main, Boston top stories, National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main | Tagged AcelRx Pharmaceuticals, Antibiotics, Biotech, clinical trials, deals, FDA, La Jolla Pharmaceutical, Life Sciences, Melinta Therapeutics, Tetraphase Pharmaceuticals, urinary tract infections | Comments Off on La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding WarMelinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition
Melinta Therapeutics and Tetraphase Pharmaceuticals, two antibiotics companies that have struggled separately, will now see if they have better luck together. Morristown, NJ-based Melinta has reached a deal to acquire Tetraphase (NASDAQ: TTPH) for $39 million in cash up front. Tetraphase shareholders could earn up to $16 million more if the Watertown, MA-based biotech’s sole […]
Posted in Boston blog main, Boston top stories, National blog main, New York, New York blog main, New York top stories | Tagged AcelRx Pharmaceuticals, Antibiotic, Biotech, deals, Deerfield Management, eravacycline, La Jolla Pharmaceutical, Life Sciences, Melinta Therapeutics, Tetraphase Pharmaceuticals | Comments Off on Melinta Expands Antibiotics Lineup With $39M Tetraphase AcquisitionBio Roundup: Light For Spark, California Drug Law, IPO Queue & More
In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through several towns across the state and, as of this writing, have barely been contained. With our minds on friends and loved ones affected by […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged AbbVie, abemaciclib, Abingworth, AcelRx Pharmaceuticals, Affordable Care Act, Allena Pharmaceuticals, amazon, AnaptysBio, Ardelyx, Biotech, Broad Institute, Broad Institute of Harvard and MIT, Deerfield Management, Eli Lilly, FDA, Flexion Therapeutics, Food and Drug Administration, Fred Hutchinson Cancer Research Center, Gene Therapy, IPO, Jerry Brown, KalVista Pharmaceuticals, Life Sciences, luxturna, Merck, Mission Bay, OrthoPediatrics, Spark Thearpeutics, Spero Therapeutics, Turnstone Biologics, VirionHealth | Comments Off on Bio Roundup: Light For Spark, California Drug Law, IPO Queue & MoreMany Biotechs Need Inside IPO Help, But Selecta Is An Extreme Case
Because public investors have had a more discerning attitude toward biotech IPOs this year, insiders have had to step up to help their companies go public. One extreme example is Selecta Biosciences, which just priced its offering late Tuesday with its pre-IPO investors likely buying around 60 percent of the shares. Selecta, of Watertown, MA, […]
Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, San Francisco blog main | Tagged AcelRx Pharmaceuticals, Back Bay Life Science Advisors, BeiGene, Cancer Prevention Pharmaceuticals, Celgene, Cempra, Corvus Pharmaceuticals, deals, Dicerna Therapeutics, Gemphire Therapeutics, Intellia Therapeutics, IPOs, Jonathan Gertler, Life Sciences, Merus, Oncobiologics, Patrick Soon-Shiong, PhaseRx, ProteoStasis Therapeutics, RA Capital Management, Rajeev Shah, Renaissance Capital, Selecta Biosciences, Spring Bank Pharmaceuticals, Syros Pharmaceuticals, VC | Comments Off on Many Biotechs Need Inside IPO Help, But Selecta Is An Extreme CaseForesite Capital Closes $100M Fund for Late-Stage Biotechs
Biotech venture capital isn’t what it used to be, but there’s still money to invest in healthcare. Now one biotech investment firm just starting out has found $100 million to plow into “late-stage” companies. Foresite Capital Management, a San Francisco- and New York-based firm founded by Jim Tananbaum in 2011, said today it has officially […]
Posted in National blog main, New York blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged AcelRx Pharmaceuticals, Biotech, Dorothy Margolskee, Finances, Foresite Capital Management, Intarcia Therapeutics, Jim Tananbaum, Keryx Pharmaceuticals, Life Sciences, people, Prospect Venture Partners, Puma Biotechnology, Solta Medical, Tarsa Therapeutics | Comments Off on Foresite Capital Closes $100M Fund for Late-Stage BiotechsExclusive: Skyline Ventures Cuts Partners, Postpones Fundraising
Skyline Ventures, one of the high-profile venture firms in the U.S. biotech and medical device business over the past 15 years, has let go three of its six partners and postponed plans to raise a new venture fund, Xconomy has learned. Skyline, which has offices in Palo Alto, CA, Waltham, MA, and Stamford, CT, raised […]
Posted in Boston blog main, Boston top stories, National, National blog main, National top stories, San Francisco blog main, San Francisco top stories | Tagged AcelRx Pharmaceuticals, Biotech, California Public Employees' Retirement System, Canaan Partners, CMEA Capital, Genocea Biosciences, GlaxoSmithKline, KAI Pharmaceuticals, Kleiner Perkins Caufield & Byers, Life Sciences, MAP Pharmaceuticals, Medivance, Merck, NimbleGen Systems, NovaCardia, OVP Venture Partners, people, Prospect Venture Partners, Scale Venture Partners, Sirtris Pharmaceuticals, Skyline Ventures, Sofinnova Ventures, startups, Steve Burrill, Steve Hoffman, Sutro Biopharma, Tetraphase Pharmaceuticals, VC, Versant Ventures, Xenoport | 2 CommentsAcelRx Gets $40M in IPO
Redwood City, CA-based AcelRx Pharmaceuticals (NASDAQ: ACRX) said today it has priced its initial public offering. The company sold 8 million shares at $5 apiece, meaning it raised gross proceeds of $40 million. That’s far less than the $12 to $14 per share price range AcelRx had forecasted on Jan. 31. The company, a developer […]
Posted in National briefs, San Francisco, San Francisco briefs | Tagged AcelRx Pharmaceuticals, Biotech, Canaccord Genuity, Cowen & Co., deals, Finances, JMP Securities, Life Sciences, Piper Jaffray | Comments Off on AcelRx Gets $40M in IPOAcelRx Pharmaceuticals Receives $8,000,800 New Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5751e8cb-4813-4721-9a75-5ba6b774a53b&Preview=1 Date 9/21/2010 Company Name AcelRx Pharmaceuticals Mailing Address 575 Chesapeake Drive Redwood City, CA 94063 Company Description The company is developing a novel drug-device therapy for the treatment of breakthrough pain. Website http://www.acelrx.com/ Transaction Type Debt Transaction Amount $8,000,800 Transaction Round Undisclosed Proceeds Purposes Proceeds purposes were not disclosed. SEC regulatory […]
Posted in San Francisco, San Francisco VentureDeal VC | Tagged AcelRx Pharmaceuticals, SanFranciscoVC, Undisclosed | Comments Off on AcelRx Pharmaceuticals Receives $8,000,800 New FinancingAcelRx Pharmaceuticals Obtains $14,814,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=840efaea-729a-42aa-8d38-3bae8be0499f&Preview=1 Date 12/31/2009 Company Name AcelRx Pharmaceuticals Mailing Address 575 Chesapeake Drive Redwood City, CA 94063 Company Description The company is developing a novel drug-device therapy for the treatment of breakthrough pain. Website http://www.acelrx.com/ Transaction Type Venture Equity Transaction Amount $14,814,000 Transaction Round Undisclosed Proceeds Purposes Proceeds purposes were not disclosed. M&A […]
Posted in San Francisco, San Francisco VentureDeal VC | Tagged AcelRx Pharmaceuticals, Alta Partners, SanFranciscoVC, Three Arch Partners | Comments Off on AcelRx Pharmaceuticals Obtains $14,814,000 New RoundArchives
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- September 2004
- June 2004
- May 2004
- March 2004
- February 2004
- January 2004
- December 2003
- June 2003
- May 2003
- March 9
Meta